Nanophase Reports Record Third Quarter Revenue and Profit

Rhea-AI Summary

Nanophase Technologies reported record financial results for Q3 2024, with revenue reaching $16.9 million, a 112% increase from Q3 2023. The company's Solésence subsidiary achieved $13.6 million in revenue, up 171% year-over-year. Q3 gross profit hit a record $6.1 million, with net income of $3 million compared to a $1.4 million loss in Q3 2023.

For the nine months ended September 30, revenue reached $39.8 million, exceeding full-year 2023 revenue by $2.5 million. The company expanded operations by adding three new ISO 6 clean rooms and implementing additional automation across key processes.

Positive

• Record Q3 revenue of $16.9M, up 112% YOY
• Solésence revenue increased 171% to $13.6M
• Q3 gross profit margin improved to 36% from 19%
• Record Q3 net income of $3M vs $1.4M loss in 2023
• Nine-month revenue already exceeded full-year 2023 by $2.5M
• Operational expansion with 3 new clean rooms

Negative

• None.

—Nanophase Reports Q3 Revenue Record at $16.9 Million with Solésence Revenue up 171% YOY  

—Record $3 Million in Q3 Profit

ROMEOVILLE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced record financial results for the third quarter ended September 30, 2024.   

Jess Jankowski, President and Chief Executive Officer, commented: “We are pleased to have closed out another successful quarter as 2024 continues to be the breakout year that we had expected. In the third quarter, alongside record top-line revenue we also achieved record gross profit, record operating income, and record net income.”  

Kevin Cureton, Chief Operating Officer, commented: “We continue to see the impact of our improvements, along with continuing dynamic growth of the Solésence business, as our nine-month revenue for 2024 has already exceeded our full-year 2023 revenue by $2.5 million. In the third quarter, we expanded our capabilities and implemented additional automation while manufacturing and shipping a record number of units of finished goods to support record-breaking revenue growth and profitability.” 

Third Quarter Financial Highlights 

• Revenue for the third quarter was a record $16.9 million, vs. $8 million for the same period in 2023, a 112% increase.  
  • Solésence revenue was $13.6 million, vs. $5 million for the same period in 2023, a 171% increase.  
• Gross profit for the third quarter was a record $6.1 million, vs $1.5 million for the same period in 2023, a 299% increase.  
  • As a percentage of sales, gross profit was 36%, vs. 19% for the same period in 2023. 
• Net income for the third quarter was a record $3 million, vs. a net loss of $1.4 million for the same period in 2023.  
  • Net income as a percentage of sales was 18% for the period. 

Nine-Month Financial Highlights 

• Revenue for the nine months ended September 30 was a record $39.8 million, a 36% increase over the same period in 2023. 
  • Nine-month revenue for 2024 exceeded full-year 2023 revenue by $2.5 million. 
• Gross profit for the nine months ended September 30 was $13.4 million, an 83% increase over the same period in 2023. 
• Net income for the nine months ended September 30 was $4.8 million, a $7.1 million swing from the $2.3 million loss in the same period in 2023. 

Operational Highlights 

Record Q3 production  

• Solésence manufactured and shipped a record number of units of finished goods, both on a monthly and on a quarterly basis, throughout Q3. 
  

Automation implementation 

• We added additional automation across two key processes to expand production capacity and improve labor efficiency. 
  

Clean room expansion 

• We added 3 new ISO 6 clean rooms for the filling and assembly of products. This brings our total to 8 clean rooms, adding capacity to enable new opportunities both domestically and on a global basis. 
  

“Our results are a testament to the hard work of our entire team, as well as the ongoing partnership with the brands we work with, and support from our suppliers, investors, and other critical stakeholders. Our strategy is bearing fruit, and we are all optimistic about our future. We look forward to sharing more during our call tomorrow,” concluded Jankowski. 

Conference Call 

Nanophase will host its Third Quarter Conference Call on Thursday, October 31, 2024, at 1:00 p.m. CDT, 2:00 p.m. EDT, to discuss its financial results and provide a business and financial update. On the call will be Jess Jankowski, the Company’s President & CEO, joined by Kevin Cureton, the Company’s Chief Operating Officer. 

Participant Registration:  

https://register.vevent.com/register/BI47b1370207234aaf827679d05baa2c17  

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call has begun. If you forget your PIN prior to the conference call, you can simply re-register.  

Listen-Only Webcast & Replay:  

https://edge.media-server.com/mmc/p/hmq3nfn9  

The call may also be accessed through the company’s website, at www.nanophase.com, by clicking on Investor Relations, Investor News, and the links in this conference call announcement release. Please connect to the conference at least five minutes before the call is scheduled to begin.  

FINANCIAL RESULTS AND NON-GAAP INFORMATION 

Use of Non-GAAP Financial Information 

Nanophase believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP. 

About Nanophase Technologies 

Nanophase Technologies Corporation (OTCQB: NANX), www.nanophase.com, is a leading innovator in mineral-based and scientifically driven healthcare solutions across beauty and life science categories, as well as other legacy advanced materials applications. Leveraging a platform of integrated, patented and proprietary technologies, the Company creates products with unique performance, enhancing consumers' health and well-being. We deliver commercial quantity and quality engineered materials both as ingredients and as part of fully formulated products in a variety of formats.   

About Solésence Beauty Science 

Solésence, www.solesence.com, a wholly owned subsidiary of Nanophase Technologies, is changing the face of skin health with patented, mineral-based technology that is embraced by leading performance-driven and clean beauty brands alike. Our patented products for brands transform the way mineral actives look, feel and function — enabling textures never-before-seen in the mineral space and inclusivity never-before-seen in the sun care space. Solésence’s innovative formulations offer best-in-class UV protection, unparalleled free radical prevention to protect against pollution, and enhanced antioxidant performance.  

Forward-Looking Statements 

This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 28, 2024. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.   

Investor Relations Contact: 

Phone: (630) 771-6736 

NANOPHASE TECHNOLOGIES CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited Consolidated Condensed)
			(in thousands except share and per share data)
			September 30,				December 31,
			2024				2023
ASSETS			(Unaudited)
Current assets:
	Cash		$	2,925			$	1,722
	Trade accounts receivable, less allowance for doubtful accounts of $446
		for September 30, 2024 and $225 for December 31, 2023		8,732				3,467
	Inventories, net			15,043				10,031
	Prepaid expenses and other current assets			3,061				1,082
		Total current assets		29,761				16,302
	Equipment and leasehold improvements, net			10,230				8,668
	Operating leases, right of use			8,054				7,907
	Other assets, net			2				4
			$	48,047			$	32,881
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Lines of credit - accounts receivable, related party			-				2,810
	Current portion of long term debt - inventory, related party			5,200				-
	Current portion of long term debt, related party			1,000				-
	Current portion of long term debt, related party			-				2,000
	Current portion of operating lease obligations			1,091				1,297
	Accounts payable			6,562				6,260
	Current portion of deferred revenue			6,228				2,353
	Accrued expenses			3,207				869
		Total current liabilities		23,288				15,589
	Long-term portion of operating lease obligations			9,346				9,152
	Long-term debt - inventory, related party			-				5,000
	Long-term debt, related party			-				1,000
	Asset retirement obligation			244				238
		Total long-term liabilities		9,590				15,390
Stockholders' equity:
	Preferred stock, $.01 par value, 24,088 shares authorized and
		no shares issued and outstanding		-				-
	Common stock, $.01 par value, 95,000,000 and 60,000,000 shares authorized;
		69,949,646 and 49,627,254 shares issued and outstanding on September 30, 2024
		and December 31, 2023, respectively		699				496
	Additional paid-in capital			114,339				106,069
	Accumulated deficit			(99,869	)			(104,663	)
		Total stockholders' equity		15,169				1,902
Total liabilities and shareholders' equity			$	48,047			$	32,881

NANOPHASE TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
				Three months ended							Nine months ended
				September 30,							September 30,
				2024			2023				2024			2023
Revenue:
	Product revenue			$	16,785		$	7,746			$	39,479		$	28,925
	Other revenue				81			212				301			361
		Net revenue			16,866			7,958				39,780			29,286
	Cost of revenue				10,764			6,428				26,358			21,932
		Gross profit			6,102			1,530				13,422			7,354
Operating expense:
	Research and development expense				970			1,057				2,746			3,052
	Selling, general and administrative expense				1,934			1,695				5,321			5,951
Income from operations					3,198			(1,222	)			5,355			(1,649	)
	Interest income			-				-			-				-
	Interest expense				153			214				562			613
	Other income, net			-				-			-				-
Income before provision for income taxes					3,045			(1,436	)			4,793			(2,262	)
Provision for income taxes					-			-				-			-
Net income (loss)				$	3,045		$	(1,436	)		$	4,793		$	(2,262	)
Net income (loss) per share-basic				$	0.04		$	(0.03	)		$	0.08		$	(0.05	)
Weighted average number of common shares outstanding - basic					69,873,394			49,598,591				59,778,119			49,532,395
Net income (loss) per share-diluted				$	0.04		$	(0.03	)		$	0.08		$	(0.05	)
Weighted average number of common shares outstanding - diluted					71,935,394			49,598,581				61,725,119			49,532,395
NANOPHASE TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
				Three months ended							Nine months ended
				September 30,							September 30,
				2024			2023				2024			2023
Revenue:
	Product revenue			$	16,785		$	7,746			$	39,479		$	28,925
	Other revenue				81			212				301			361
		Net revenue			16,866			7,958				39,780			29,286
	Cost of revenue detail:
	Depreciation				219			159				663			481
	Non-Cash equity compensation				26			27				80			85
	Other costs of revenue				10,519			6,242				25,615			21,366
		Cost of revenue			10,764			6,428				26,358			21,932
			Gross profit		6,102			1,530				13,422			7,354
Operating expense:
	Research and development expense detail:
	Depreciation				6			7				17			21
	Non-Cash equity compensation				34			47				99			136
	Other research and development expense				930			1,003				2,630			2,895
		Research and development expense			970			1,057				2,746			3,052
	Selling, general and administrative expense detail:
	Depreciation and amortization				6			8				20			22
	Non-Cash equity compensation				100			136				298			374
	Other selling, general and administrative expense				1,828			1,551				5,003			5,555
		Selling, general and administrative expense			1,934			1,695				5,321			5,951
Income from operations					3,198			(1,222	)			5,355			(1,649	)
	Interest expense				153			214				562			613
	Other income, net				-			-				-			-
Income before provision for income taxes					3,045			(1,436	)			4,793			(2,262	)
Provision for income taxes					-			-				-			-
Net income (loss)				$	3,045		$	(1,436	)		$	4,793		$	(2,262	)
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):
	Addback Interest, net				153			214				562			613
	Addback Depreciation/Amortization				231			174				700			524
	Addback Non-Cash Equity Compensation				160			210				477			595
	Subtract Non-Cash Other Income				-			-				-			-
	Adjusted EBITDA			$	3,589		$	(838	)		$	6,532		$	(530	)

FAQ

What was Nanophase Technologies (NANX) Q3 2024 revenue?

Nanophase Technologies reported record Q3 2024 revenue of $16.9 million, representing a 112% increase from Q3 2023.

How much did Solésence revenue grow in Q3 2024?

Solésence revenue grew 171% year-over-year to $13.6 million in Q3 2024, compared to $5 million in Q3 2023.

What was NANX's net income for Q3 2024?

Nanophase Technologies reported a record net income of $3 million in Q3 2024, compared to a net loss of $1.4 million in Q3 2023.

How many clean rooms did Nanophase add in Q3 2024?

Nanophase added 3 new ISO 6 clean rooms for filling and assembly, bringing their total to 8 clean rooms.